<div id="readability-page-1"><div><p>Sino Biopharmaceutical CEO Eric Tse discusses the &#34;survival&#34; necessity of China's rapid clinical trial growth and his open-ended approach to deals in 2026. He speaks to Bloomberg TV's Haslinda Amin on the sidelines of the 2026 World Economic Forum in Davos, Switzerland.</p><p><span>Bloomberg videos</span>, provided by MT Newswires</p></div></div>

159929

159837

159859

512290

159849

01177

588250

516500

588130

589720

<p>Sino Biopharmaceutical CEO Eric Tse discusses the "survival" necessity of China's rapid clinical trial growth and his open-ended approach to deals in 2026. He speaks to Bloomberg TV's Haslinda Amin on the sidelines of the 2026 World Economic Forum in Davos, Switzerland.Bloomberg videos, provided by MT Newswires</p>

marketscreener

China Universal 800 Health Care ETF

E Fund CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

Guotai CSI Bio-medicine ETF

China Merchants CSI Biotechnology Theme ETF

SINO BIOPHARM

Penghua SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai SSE STAR Brand Name Drug ETF

Sino Biopharma CEO on China's Rapid Clinical Trial Growth